Pfizer’s COVID vaccine success is worth an extra $14 billion to the US pharma giant – ABC News

The success of its COVID vaccine, and the challenges faced by some of its rivals, look set to earn US pharmaceutical giant Pfizer at least an extra $US11 billion ($14.2 billion) in revenue this year.
Key points:

• Pfizer has raised its 2021 revenue forecasts for COVID vaccine sales by 73 per cent
• The company is hoping to ramp up production to 2.5 billion doses this year and three billion in 2022
• Pfizer is evaluating a prototype to include the South African variant and expects annual flu-style vaccinations…

Click here to view the original article.